RxDoctor Payments Data

Cathryn Jenkins, NP

Adult Health · Batavia, OHNPI 1831231372

Payments from drug & device makers

$1,429in general payments, 2019–2025

Across 43 payments — averaging $33.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$397
  • Teva Pharmaceuticals USA, Inc.$303
  • Otsuka America Pharmaceutical, Inc.$196
  • Acadia Pharmaceuticals Inc$155
  • Sun Pharmaceutical Industries Inc.$144
  • Avanir Pharmaceuticals, Inc.$106
  • plus $129 from 2 others

What the payments were for

  • Food & beverage$1,31792%
  • Education$1118%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,429 in reported general payments places this provider in the 75th percentile of 1,184 adult health providers in Ohio.

See all adult health providers in Ohio

Medicare billing

Part B allowed, 2024
$255,290
Medicare patients
295
Services billed
3,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate14$52,631
TrintellixVortioxetine Hydrobromide21$6,595
BelsomraSuvorexant16$3,030
Sertraline Hcl266$2,668
Desvenlafaxine Succinate ErDesvenlafaxine Succinate29$2,203
Mirtazapine52$1,662
Lorazepam176$1,536
Memantine Hcl26$1,262
Alprazolam116$1,011
Trazodone Hcl78$747
Clonazepam61$694
Escitalopram Oxalate47$628
Buspirone Hcl51$624
Duloxetine Hcl21$508
Venlafaxine Hcl ErVenlafaxine Hcl23$496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$155$52,63114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,184 adult health providers in Ohio.

Other adult health in Batavia

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →